Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 12, 2003

View Archived Issues

EACS presentations cover clinical results for atazanavir

Good hemodynamic profile associated with selodenoson in chronic atrial fibrillation

ABT-239, a nonimidazole H3 receptor antagonist with cognition-enhancing effects

NXY-059 enhances tenecteplase-induced neuroprotection in rabbits with embolic stroke

Several series of chemokine CCR3 antagonists presented by GSK

Novel glucocorticoid receptor modulators identified at Boehringer Ingelheim

Janssen claims dual 5-HT reuptake inhibitors/alpha2-adrenoceptor antagonists and their use

Recent patent covers new liver X receptor agonists discovered by GSK scientists

Schering AG presents new glucocorticoid receptor ligands

Spanish researchers design new adenosine A2A and/or A2B antagonists

New BZ receptor ligands with neurotrophic activity developed at Sanofi-Synthelabo

Eligard products receive Canadian approval

Phase IIb trials of pralnacasan in rheumatoid arthritis discontinued

Milestone reached in osteoporosis collaboration between Celltech and Amgen

Nefazodone withdrawn from market in Canada

Lexicon achieves first performance milestone in Genentech alliance

Novartis and Medicines for Malaria Venture to develop pediatric Coartem

Phase II dose-to-rash study of Tarceva

Roche acquires rights to CS-023

Savient and Teva terminate acquisition discussions

Novo Nordisk obtains license option for Islet Neogenesis Therapy

Vertex reports Q3 financial results and product pipeline update

A tetrapeptide reported effective in reducing infarct size following AMI

No adverse cardiac electrophysiological effects associated with ivabradine

Comparative study of binodenoson and adenosine in PS-SPECT

BG-9928 improves sodium excretion in heart failure patients

ETC-642 elevates HDL cholesterol in atherosclerosis

Panacea selects neuroprotective lead compound that acts by inhibiting oxidative stress

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...